Structured evidence table for Probiotics Gas Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Probiotics Gas Meta-Analysis | RESULTS: This study synthesized evidence from 16 case-control studies and 6 randomized controlled trials (RCTs) through a systematic review and meta-analysis. | 1 | Li J (2026) | Alterations of short-chain fatty acids in depression and effects of probiotics/prebiotics interventions on levels and clinical symptoms: a systematic review and meta-analysis. |
| Probiotics Gas Meta-Analysis | The case-control analysis found significantly lower plasma levels of acetate (SMD = -0.51, 95% CI [-0.86, -0.15]), propionate (SMD = -0.65, 95% CI [-1.06, -0.25]), butyrate (SMD = -0.43, 95% CI [-0.72, -0.15]), and valerate(SMD = -1.09, 95% CI [-2.02, -0.17]) in individuals with depression compared to healthy controls. | 1 | Li J (2026) | Alterations of short-chain fatty acids in depression and effects of probiotics/prebiotics interventions on levels and clinical symptoms: a systematic review and meta-analysis. |
| Probiotics Gas Meta-Analysis | In fecal samples, no significant differences were found in the three main SCFAs, but fecal valerate was decreased and isobutyrate was increased. | 1 | Li J (2026) | Alterations of short-chain fatty acids in depression and effects of probiotics/prebiotics interventions on levels and clinical symptoms: a systematic review and meta-analysis. |
| Probiotics Gas Meta-Analysis | BACKGROUND: Short-chain fatty acids (SCFAs) are essential metabolites in the interaction between gut microbiota and the host. | 1 | Li J (2026) | Alterations of short-chain fatty acids in depression and effects of probiotics/prebiotics interventions on levels and clinical symptoms: a systematic review and meta-analysis. |
| Probiotics Gas Meta-Analysis | 1 Strain Evidence strength Proposed Mechanism Lactobacillus acidophilus DDS-1 ( ) 2016 Pakdaman et al. | 3 | Perets Tsachi Tsadok (2026) | Lactose intolerance and probiotics: from pathophysiological mechanisms to clinical applications |
| Probiotics Gas Meta-Analysis | Randomized, double-blind, placebo-controlled crossover trial reported reduced lactose intolerance symptom scores after supplementation, with improved tolerance to lactose challenge High beta-galactosidase (lactase) activity enhances lactose hydrolysis; may reduce colonic lactose load and gas production; potential modulation of gut microbiota Bifidobacterium animalis subsp. | 3 | Perets Tsachi Tsadok (2026) | Lactose intolerance and probiotics: from pathophysiological mechanisms to clinical applications |
| Probiotics Gas Meta-Analysis | Demonstrated support for lactose digestion in vitro and in randomized placebo- and lactase-controlled clinical trials; associated with reduced gastrointestinal symptoms during lactose exposure beta-galactosidase delivery to the small intestine and enhanced lactose breakdown; may shift fermentation toward less gas-producing pathways Multi-strain probiotic formulation (Bio-25) ( ) 2020 Gingold-Belfer et al. | 3 | Perets Tsachi Tsadok (2026) | Lactose intolerance and probiotics: from pathophysiological mechanisms to clinical applications |
Source documents